Download PDF
Horm Metab Res 2016; 48(07): 484-488
DOI: 10.1055/s-0042-108196
Endocrine Research
© Georg Thieme Verlag KG Stuttgart · New York

Effects of Type 1 Insulin-Like Growth Factor Receptor Silencing in a Human Adrenocortical Cell Line

T. C. Ribeiro
1   Unidade de Endocrinologia do Desenvolvimento, Laboratório de Hormônios e Genética Molecular, LIM/42, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
,
A. A. Jorge
1   Unidade de Endocrinologia do Desenvolvimento, Laboratório de Hormônios e Genética Molecular, LIM/42, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
2   Unidade de Endocrinologia Genética Laboratório de Endocrinologia Celular e Molecular, LIM/25, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
,
L. R. Montenegro
1   Unidade de Endocrinologia do Desenvolvimento, Laboratório de Hormônios e Genética Molecular, LIM/42, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
,
M. Q. Almeida
1   Unidade de Endocrinologia do Desenvolvimento, Laboratório de Hormônios e Genética Molecular, LIM/42, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
,
B. Ferraz-de-Souza
3   Unidade de Doenças Osteometabólicas, Laboratório de Carboidratos e Radioimunoensaios LIM/18. Disciplina de Endocrinologia e Metabologia da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
,
M. Y. Nishi
1   Unidade de Endocrinologia do Desenvolvimento, Laboratório de Hormônios e Genética Molecular, LIM/42, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
,
B. B. Mendonca
1   Unidade de Endocrinologia do Desenvolvimento, Laboratório de Hormônios e Genética Molecular, LIM/42, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
,
A. C. Latronico
1   Unidade de Endocrinologia do Desenvolvimento, Laboratório de Hormônios e Genética Molecular, LIM/42, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
› Author Affiliations
Further Information

Publication History

received 29 July 2015

accepted after second revision 28 April 2016

Publication Date:
31 May 2016 (online)

Also available at
    Permissions and Reprints

Abstract

Type 1 insulin-like growth factor receptor (IGF-1R) is overexpressed in a variety of human cancers, including adrenocortical tumors. The aim of the work was to investigate the effects of IGF-1R downregulation in a human adrenocortical cell line by small interfering RNA (siRNA). The human adrenocortical tumor cell line NCI H295R was transfected with 2 specific IGF1R siRNAs (# 1 and # 2) and compared with untreated cells and a negative control siRNA. IGF1R expression was determined by quantitative reverse-transcription PCR (qRTPCR) and Western blot. The effects of IGF-1R downregulation on cell proliferation and apoptosis were assessed. IGF-1R levels were significantly decreased in cells treated with IGF-1R siRNA # 1 or # 2. Relative expression of IGF1R mRNA decreased approximately 50% and Western blot analysis revealed a 30% of reduction in IGF-1R protein. Downregulation of this gene resulted in 40% reduction in cell growth in vitro and 45% increase in apoptosis using siRNA # 2. These findings demonstrate that decreasing IGF-1R mRNA and protein expression in NCI H295R cells can partially inhibit adrenal tumor cell growth in vitro. Targeting IGF1R is a promising therapy for pediatric malignant adrenocortical tumor and can still be an option for adult adrenocortical cancer based on personalized genomic tumor profiling.

Key words

IGF system - IGF-1R - siRNA - adrenocortical tumors
 

  • References

  • 1 Fottner C, Hoeflich A, Wolf E, Weber MM. Role of the insulin-like growth factor system in adrenocortical growth control and carcinogenesis. Horm Metab Res 2004; 36: 397-405
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000; 92: 1472-1489
    CrossrefPubMedGoogle Scholar
  • 3 Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab 2013; 98: 4551-4564
    CrossrefPubMedGoogle Scholar
  • 4 Sandrini R, Ribeiro RC, DeLacerda L. Childhood adrenocortical tumors. J Clin Endocrinol Metab 1997; 82: 2027-2031
    CrossrefPubMedGoogle Scholar
  • 5 Latronico AC, Chrousos GP. Extensive personal experience: adrenocortical tumors. J Clin Endocrinol Metab 1997; 82: 1317-1324
    CrossrefPubMedGoogle Scholar
  • 6 Bertherat J, Bertagna X. Pathogenesis of adrenocortical cancer. Best Pract Res Clin Endocrinol Metab 2009; 23: 261-271
    CrossrefPubMedGoogle Scholar
  • 7 Fassnacht M, Libe R, Kroiss M, Allolio B. Adrenocortical carcinoma: a clinician’s update. Nat Rev Endocrinol 2011; 7: 323-325
    CrossrefPubMedGoogle Scholar
  • 8 de Sousa GR, Soares IC, Faria AM, Domingues VB, Wakamatsu A, Lerario AM, Alves VA, Zerbini MC, Mendonca BB, Fragoso MC, Latronico AC, Almeida MQ. DAX1 Overexpression in Pediatric Adrenocortical Tumors: A Synergic Role with SF1 in Tumorigenesis. Horm Metab Res 2015; 47: 656-661
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Assie G, Letouze E, Fassnacht M, Jouinot A, Luscap W, Barreau O, Omeiri H, Rodriguez S, Perlemoine K, René-Corail F, Elarouci N, Sbiera S, Kroiss M, Allolio B, Waldmann J, Quinkler M, Mannelli M, Mantero F, Papathomas 14 T, De Krijger R, Tabarin A, Kerlan V, Baudin E, Tissier F, Dousset B, Groussin L, Amar L, Clauser E, Bertagna X, Ragazzon B, Beuschlein F, Libé R, de Reyniès A, Bertherat J. Integrated genomic characterization of adrenocortical carcinoma. Nat Genet 2014; 46: 607-612
    CrossrefPubMedGoogle Scholar
  • 10 Beuschlein F, Fassnacht M, Assié G, Calebiro D, Stratakis CA, Osswald A, Ronchi CL, Wieland T, Sbiera S, Faucz FR, Schaak K, Schmittfull A, Schwarzmayr T, Barreau O, Vezzosi D, Rizk-Rabin M, Zabel U, Szarek E, Salpea P, Forlino A, Vetro A, Zuffardi O, Kisker C, Diener S, Meitinger T, Lohse MJ, Reincke M, Bertherat J, Strom TM, Allolio B. Constitutive activation of PKA catalytic subunit in adrenal Cushing’s syndrome. N Engl J Med 2014; 370: 1019-1028
    Google Scholar
  • 11 Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM, Jolly S, Miller BS, Giordano TJ, Hammer GD. Adrenocortical carcinoma. Endocr Rev 2014; 35: 282-326
    CrossrefPubMedGoogle Scholar
  • 12 Gaston V, Le Bouc Y, Soupre V, Burglen L, Donadieu J, Oro H, Audry G, Vazquez MP, Gicquel C. Analysis of the methylation status of the KCNQ1OT and H19 genes in leukocyte DNA for the diagnosis and prognosis of Beckwith-Wiedemann syndrome. Eur J Hum Genet 2001; 9: 409-418
    CrossrefPubMedGoogle Scholar
  • 13 Bertoin F, Letouze E, Grignani P, Patey M, Rossignol S, Libe R, Pasqual C, Lardière-Deguelte S, Hoeffel-Fornes C, Gaillard D, Previderè C, Delemer B, Lalli E. Genome-wide paternal uniparental disomy as a cause of Beckwith-Wiedemann syndrome associated with recurrent virilizing adrenocortical tumors. Horm Metab Res 2015; 47: 497-503
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Gicquel C, Bertagna X, Schneid H, Francillard-Leblond M, Luton JP, Girard F, Le Bouc Y. Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. J Clin Endocrinol Metab 1994; 78: 1444-1453
    CrossrefPubMedGoogle Scholar
  • 15 Gicquel C, Raffin-Sanson ML, Gaston V, Bertagna X, Plouin PF, Schlumberger M, Louvel A, Luton JP, Le Bouc Y. Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. J Clin Endocrinol Metab 1997; 82: 2559-2565
    CrossrefPubMedGoogle Scholar
  • 16 Giordano TJ, Thomas DG, Kuick R, Lizyness M, Misek DE, Smith AL, Sanders D, Aljundi RT, Gauger PG, Thompson NW, Taylor JM, Hanash SM. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol 2003; 162: 521-531
    CrossrefPubMedGoogle Scholar
  • 17 de Fraipont F, El Atifi M, Cherradi N, Le Moigne G, Defaye G, Houlgatte R, Bertherat J, Bertagna X, Plouin PF, Baudin E, Berger F, Gicquel C, Chabre O, Feige JJ. Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab 2005; 90: 1819-1829
    CrossrefPubMedGoogle Scholar
  • 18 Rosenzweig SA, Atreya HS. Defining the pathway to insulin-like growth factor system targeting in cancer. Biochem Pharmacol 2010; 80: 1115-1124
    CrossrefPubMedGoogle Scholar
  • 19 Almeida MQ, Fragoso MC, Lotfi CF, Santos MG, Nishi MY, Costa MH, Lerario AM, Maciel CC, Mattos GE, Jorge AA, Mendonca BB, Latronico AC. Expression of insulin-like growth factor-II and its receptor in pediatric and adult adrenocortical tumors. J Clin Endocrinol Metab 2008; 93: 3524-3531
    CrossrefPubMedGoogle Scholar
  • 20 Maloney EK, McLaughlin JL, Dagdigian NE, Garrett LM, Connors KM, Zhou XM, Blättler WA, Chittenden T, Singh R. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 2003; 63: 5073-5083
    PubMedGoogle Scholar
  • 21 Chernicky CL, Yi L, Tan H, Gan SU, Ilan J. Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo. Cancer Gene Ther 2000; 7: 384-395
    CrossrefPubMedGoogle Scholar
  • 22 Rana TM. Illuminating the silence: understanding the structure and function of small RNAs. Nat Rev Mol Cell Biol 2007; 8: 23-36
    CrossrefPubMedGoogle Scholar
  • 23 Gazdar AF, Oie HK, Shackleton CH, Chen TR, Triche TJ, Myers CE, Chrousos GP, Brennan MF, Stein CA, La Rocca RV. Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis. Cancer Res 1990; 50: 5488-5496
    PubMedGoogle Scholar
  • 24 Werner H, Roberts Jr CT. The IGFI receptor gene: a molecular target for disrupted transcription factors. Gene Chromosom Canc 2003; 36: 113-120
    PubMedGoogle Scholar
  • 25 Kanter-Lewensohn L, Dricu A, Girnita L, Wejde J, Larsson O. Expression of insulin-like growth factor-1 receptor (IGF-1R) and p27Kip1 in melanocytic tumors: a potential regulatory role of IGF-1 pathway in distribution of p27Kip1 between different cyclins. Growth Factors 2000; 17: 193-202
    CrossrefPubMedGoogle Scholar
  • 26 Weber MM, Fottner C, Liu SB, Jung MC, Engelhardt D, Baretton GB. Overexpression of the insulin-like growth factor I receptor in human colon carcinomas. Cancer 2002; 95: 2086-2095
    CrossrefPubMedGoogle Scholar
  • 27 Bergmann U, Funatomi H, Yokoyama M, Beger HG, Korc M. Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res 1995; 55: 2007-2011
    PubMedGoogle Scholar
  • 28 Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 2002; 62: 2942-2950
    PubMedGoogle Scholar
  • 29 Weber MM, Auernhammer CJ, Kiess W, Engelhardt D. Insulin-like growth factor receptors in normal and tumorous adult human adrenocortical glands. Eur J Endocrinol 1997; 136: 296-303
    CrossrefPubMedGoogle Scholar
  • 30 Kamio T, Shigematsu K, Kawai K, Tsuchiyama H. Immunoreactivity and receptor expression of insulinlike growth factor I and insulin in human adrenal tumors. An immunohistochemical study of 94 cases. Am J Pathol 1991; 138: 83-91
    PubMedGoogle Scholar
  • 31 Doghman M, Wakil AE, Cardinaud B, Thomas E, Wang J, Zhao W, Peralta-Del Valle MH, Figueiredo BC, Zambetti GP, Lalli E. Regulation of Insulin-like Growth Factor-Mammalian Target of Rapamycin Signaling by MicroRNA in Childhood Adrenocortical Tumors. Cancer Res 2010; 70: 4666-4675
    CrossrefPubMedGoogle Scholar
  • 32 Yavari K, Taghikhani M, Ghannadi Maragheh M, Mesbah-Namin SA, Babaei MH. Downregulation of IGF-IR expression by RNAi inhibits proliferation and enhances chemosensitization of human colon cancer cells. Int J Colorectal Dis 2010; 25: 9-16
    CrossrefPubMedGoogle Scholar
  • 33 Dong AQ, Kong MJ, Ma ZY, Qian JF, Xu XH. Down-regulation of IGF-IR using small, interfering, hairpin RNA (siRNA) inhibits growth of human lung cancer cell line A549 in vitro and in nude mice. Cell Biol Int 2007; 31: 500-507
    CrossrefPubMedGoogle Scholar
  • 34 Cosaceanu D, Carapancea M, Alexandru O, Budiu R, Martinsson HS, Starborg M, Vrabete M, Kanter L, Lewensohn R, Dricu A. Comparison of three approaches for inhibiting insulin-like growth factor I receptor and their effects on NSCLC cell lines in vitro. Growth Factors 2007; 25: 1-8
    CrossrefPubMedGoogle Scholar
  • 35 Niu J, Xu Z, Li XN, Han Z. siRNA-mediated type 1 insulin-like growth factor receptor silencing induces chemosensitization of a human liver cancer cell line with mutant P53. Cell Biol Int 2007; 31: 156-164
    CrossrefPubMedGoogle Scholar
  • 36 Shu S, Li X, Yang Y, Zhang Y, Li T, Liang C, Wan J. Inhibitory effect of siRNA targeting IGF-1R on endometrial carcinoma. Int Immunopharmacol 2011; 11: 244-249
    CrossrefPubMedGoogle Scholar
  • 37 Ribeiro TC, Latronico AC. Insulin-like growth factor system on adrenocortical tumorigenesis. Mol Cell Endocrinol 2012; 351: 96-100
    CrossrefPubMedGoogle Scholar
  • 38 Shen W, Xian J, Hu WL, Liu J. Effect of insulin-like growth factor and its receptor-I antibody on growth of human adrenocortical carcinoma SW-13 cell lines in vitro. Nan Fang Yi Ke Da Xue Xue Bao 2007; 27: 88-91
    PubMedGoogle Scholar
  • 39 Barlaskar FM, Spalding AC, Heaton JH, Kuick R, Kim AC, Thomas DG, Giordano TJ, Ben-Josef E, Hammer GD. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. J Clin Endocrinol Metab 2009; 94: 204-222
    CrossrefPubMedGoogle Scholar
  • 40 Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, Kroiss M, Quinn DI, Hesseltine E, Ronchi CL, Terzolo M, Choueiri TK, Poondru S, Fleege T, Rorig R, Chen J, Stephens AW, Worden F, Hammer GD. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol 2015; 16: 426-435
    CrossrefPubMedGoogle Scholar